Endovascular treatment for ischaemic stroke produces improvements in functional outcome and other clinical, imaging and safety outcome measures. The treatment effect is similar between men and women, with the latter even having more years of healthy life, as shown in the results of two recent studies.
A retrospective, multicentre cohort study has shown that the safety profile of thrombectomy in childhood stroke does not differ from the safety profile in randomized clinical trials for adults, supporting clinicians’ off-label practice of thrombectomy in paediatric patients, in the absence of high-level evidence.
Measuring heart rate variability (HRV) using a wearable echocardiography (ECG) device shows promise in detecting seizures, including the nonconvulsive episodes, proving to have high sensitivity and low false alarm rate during the night, according to data from a phase II validation study.
The 30-day mortality rates among patients undergoing transcatheter aortic valve replacement (TAVR) have decreased by more than half over the last decade, with significant differences between genders, a CENTER* collaboration analysis has shown.
Admitted patients with a cerebrovascular accident (stroke) or transient ischaemic attack (TIA) who received pharmacist intervention in the stroke prevention clinic (SPC) are less likely to be readmitted and more likely to show improvement in surrogate markers, such as blood pressure (BP) and haemoglobin (Hb)A1c, a study has shown.
In patients with relapsing-remitting multiple sclerosis (MS), certain disease-modifying therapies (DMTs) may be more associated with serious infections than others, according to an observational study from Sweden.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.